Cefotiam

CHEMBL1296 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
525.6 g/mol
LogP
-2.4
Phase
4

A second-generation parenteral cephalosporin antibiotic with activity against gram-positive and gram-negative organisms, used in Japan and some European countries for respiratory, urinary, and surgical prophylaxis indications. It does not contain the N-methylthiotetrazole side chain and therefore lacks the alcohol interaction seen with some related drugs. It is not widely available in North America.

Khối lượng phân tử

525,6000 g/mol

LogP

-2,40

TPSA

251,00 Ų

Lipinski RO5

Không đạt

Cơ chế tác dụng

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1

InChI

InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1

Molecular Formula

C18H23N9O4S3

HBD / HBA

3 / 13

Liên kết có thể quay

10

Nguyên tử nặng

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A second-generation parenteral cephalosporin antibiotic with activity against gram-positive and gram-negative organisms, used in Japan and some European countries for respiratory, urinary, and surgical prophylaxis indications. It does not contain the N-methylthiotetrazole side chain and therefore lacks the alcohol interaction seen with some related drugs. It is not widely available in North America.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cefotiam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1296. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 43708. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.